CST3 and atrial fibrillation: Additional data from the ARISTOTLE trial furtherunderscored the superior prognostic value of cystatin C–inclusive formulas,demonstrating better discrimination for cardiovascular mortality and bleeding inanticoagulated AF patients [29].